The Effect of Mavacamten on Echocardiographic Parameters, Cardiac Function and Biomarkers in Hypertrophic Cardiomyopathy Patients, A Systematic Review and Meta-Analysis.

IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Indian heart journal Pub Date : 2025-05-27 DOI:10.1016/j.ihj.2025.05.011

Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ahmed K Awad

{"title":"The Effect of Mavacamten on Echocardiographic Parameters, Cardiac Function and Biomarkers in Hypertrophic Cardiomyopathy Patients, A Systematic Review and Meta-Analysis.","authors":"Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ahmed K Awad","doi":"10.1016/j.ihj.2025.05.011","DOIUrl":null,"url":null,"abstract":"Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).Methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library until November 2023. Results were reported as mean difference (MD) and Risk Ratio (RR) with 95% confidence intervals (CI).Results: Seven studies with 524 patients (456 with obstructive HCM and 59 with non-obstructive HCM) were included. Mavacamten significantly improved septal early diastolic mitral annular velocity (e') (MD 0.78, 95% CI [0.51 to 1.05]) and left ventricular mass index (LVMI). It reduced left ventricular outflow tract (LVOT) gradient, NT-proBNP (MD -557.14, 95% CI [-685.59 to -428.68]), and troponin levels. Improvements were also seen in left atrial volume index (MD -6.26, 95% CI [-8.88 to -3.63]) and E/e' ratios, particularly in obstructive HCM patients.Conclusion: Mavacamten enhances echocardiographic and cardiac biomarker outcomes in HCM patients on short-term follow-up. Limited data on non-obstructive HCM require cautious interpretation.","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian heart journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ihj.2025.05.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).

Methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library until November 2023. Results were reported as mean difference (MD) and Risk Ratio (RR) with 95% confidence intervals (CI).

Results: Seven studies with 524 patients (456 with obstructive HCM and 59 with non-obstructive HCM) were included. Mavacamten significantly improved septal early diastolic mitral annular velocity (e') (MD 0.78, 95% CI [0.51 to 1.05]) and left ventricular mass index (LVMI). It reduced left ventricular outflow tract (LVOT) gradient, NT-proBNP (MD -557.14, 95% CI [-685.59 to -428.68]), and troponin levels. Improvements were also seen in left atrial volume index (MD -6.26, 95% CI [-8.88 to -3.63]) and E/e' ratios, particularly in obstructive HCM patients.

Conclusion: Mavacamten enhances echocardiographic and cardiac biomarker outcomes in HCM patients on short-term follow-up. Limited data on non-obstructive HCM require cautious interpretation.

查看原文本刊更多论文

马伐卡坦对肥厚性心肌病患者超声心动图参数、心功能和生物标志物的影响：系统评价和荟萃分析

背景：评价马伐卡坦对肥厚性心肌病（HCM）患者超声心动图参数和心脏生物标志物的影响。方法：检索PubMed、SCOPUS、Web of Science和Cochrane Library，检索截止日期为2023年11月。结果报告为平均差（MD）和风险比（RR）， 95%可信区间（CI）。结果：纳入7项研究，524例患者（456例梗阻性HCM， 59例非梗阻性HCM）。马伐卡坦显著改善室间隔舒张早期二尖瓣环速度（e′）（MD = 0.78, 95% CI[0.51 ~ 1.05]）和左室质量指数（LVMI）。它降低了左心室流出道（LVOT）梯度、NT-proBNP （MD -557.14, 95% CI[-685.59至-428.68]）和肌钙蛋白水平。左房容积指数（MD -6.26, 95% CI[-8.88至-3.63]）和E/ E′比也有所改善，特别是在阻塞性HCM患者中。结论：在短期随访中，马伐卡坦可提高HCM患者的超声心动图和心脏生物标志物预后。非阻塞性HCM的有限数据需要谨慎解释。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian heart journal CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

52 days

期刊介绍： Indian Heart Journal (IHJ) is the official peer-reviewed open access journal of Cardiological Society of India and accepts articles for publication from across the globe. The journal aims to promote high quality research and serve as a platform for dissemination of scientific information in cardiology with particular focus on South Asia. The journal aims to publish cutting edge research in the field of clinical as well as non-clinical cardiology - including cardiovascular medicine and surgery. Some of the topics covered are Heart Failure, Coronary Artery Disease, Hypertension, Interventional Cardiology, Cardiac Surgery, Valvular Heart Disease, Pulmonary Hypertension and Infective Endocarditis. IHJ open access invites original research articles, research briefs, perspective, case reports, case vignette, cardiovascular images, cardiovascular graphics, research letters, correspondence, reader forum, and interesting photographs, for publication. IHJ open access also publishes theme-based special issues and abstracts of papers presented at the annual conference of the Cardiological Society of India.